Responses
Immunotherapy biomarkers
Original research
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
